Abstract
Positron emission tomography (PET) with amyloid binding tracers and 18F-fluordesoxyglucose (FDG) is used in the diagnosis of Alzheimer’s disease and other dementias. The dual-phase amyloid PET protocol acquires an early perfusion image immediately after the radiotracer injection that resembles FDG images. We studied the correlation of early phase 18F-florbetapir (eFBP) and FDG PET images by the quantitation of regional radiotracer uptake. Subjects with a neurodegenerative disease and eFBP and FDG PET scans were retrospectively selected. The PET images were normalized to the Montreal Neurological Institute template using Statistical Parametric Mapping version 12. Regional standardized uptake value ratios (SUVR) were extracted with the cerebellum serving as the reference region. Pearson’s correlation tests were performed to evaluate the regional correlation between eFBP and FDG PET images based on the quantitative measurements. Overall high correlation coefficients of up to r = 0.95 were observed in cortical regions that are in line with other studies or exceed previous results.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tripathi, M., Tripathi, M., Damle, N., Kushwaha, S., Jaimini, A., D’Souza, M.M., Sharma, R., Saw, S., Mondal, A.: Differential diagnosis of neurodegenerative dementias using metabolic phenotypes on F-18 FDG PET/CT. Neuroradiol. J. 27(1), 13–21 (2014)
Barthel, H., Seibyl, J., Sabri, O.: The role of positron emission tomography imaging in understanding Alzheimer´s disease. Expert Rev. Neurother. 15(4), 395–406 (2015)
McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack Jr., C.R., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S., Phelps, C.H.: The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. J. Alzheimer’s Assoc. 7(3), 263–269 (2011)
Ikonomovic, M.D., Klunk, W.E., Abrahamson, E.E., Mathis, C.A., Price, J.C., Tsopelas, N.D., Lopresti, B.J., Ziolko, S., Bi, W., Paljug, W.R., Debnath, M.L., Hope, C.E., Isanski, B.A., Hamilton, R.L., DeKosky, S.T.: Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alyheimer’s disease. Brain 131(6), 1630–1645 (2008)
Choi, S.R., Golding, G., Zhuang, Z., Zhang, W., Lim, N., Hefti, F., Benedum, T.E., Kilbourn, M.R., Skovronksy, D., Kung, H.F.: Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J. Nucl. Med. 50(11), 1887–1894 (2009)
Barthel, H., Sabri, O.: Florbetaben to trace amyloid-beta in the Alzheimer brain by means of PET. J. Alzheimer’s Dis. 26(s3), 117–121 (2011)
Lin, K.-J., Hsiao, I.-T., Hsu, J.-L., Huang, C.-C., Huang, K.-L., Hsieh, C.-J., Wey, S.-P., Yen, T.-C.: Imaging characteristics of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment. Eur. J. Nucl. Med. Mol. Imaging 43(7), 1304–1314 (2016)
Hsiao, I.-T., Huang, C.-C., Hsieh, C.-J., Hsu, W.-C., Wey, S.-P., Yen, T.-C., Kung, M.-P., Lin, K.-J.: Correlation of early-phase 18F-florpetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur. J. Nucl. Med. Mol. Imaging 39, 613–620 (2012)
Rostomian, A.H., Madison, C., Rabinovici, G.D., Jagust, W.J.: Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J. Nucl. Med. 52(2), 173–179 (2011)
Tiepolt, S., Hesse, S., Patt, M., Luthardt, J., Schroeter, M.L., Hoffmann, K.-T., Weise, D., Gertz, H.-J., Sabri, O., Barthel, H.: Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging 43, 1700–1709 (2016)
Daerr, S., Brendel, M., Zach, C., Mille, E., Schilling, D., Zacherl, M.J., Bürger, K., Danek, A., Pogarell, O., Schildan, A., Patt, M., Barthel, H., Sabri, O., Bartenstein, P., Rominger, A.: Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases. NeuroImage Clin. 14, 77–86 (2017)
Segovia, F., Gómez-Río, M., Sánchez-Vañó, R., Górriz, J.M., Ramírez, J., Triviño-Ibáñez, E., Carner-Pardo, C., Martínez-Lozano, M.D., Sopena-Pardo, P.: Usefulness of dual-point amyloid PET scans in appropriate use criteria: a multicenter study. J. Alzheimer’s Dis. 65(3), 765–779 (2018)
Friston, K., Ashburner, J., Kiebel, S., Nichols, T., Penny, W.: Statistical Parametric Mapping: The Analysis of Functional Brain Images. Academic Press, Amsterdam (2006)
Mazziotta, J.C., Toga, A.W., Evans, A., Fox, P., Lancaster, J.: A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). NeuroImage 2(2A), 89–101 (1995)
Kinahan, P.E., Fletcher, J.: Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. In: Seminars in Ultrasound, CT and MRI, vol. 31, no. 6, pp. 496–505 (2010)
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., Joliot, M.: Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 15(1), 273–289 (2002)
Saint-Aubert, L., Nemmi, F., Péran, P., Barbeau, E.J., Payoux, P., Chollet, F., Pariente, J.: Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur. J. Nucl. Med. Mol. Imaging 41(5), 836–843 (2014)
Camus, V., Payoux, P., Barré, L., Desgranges, B., Voisin, T., Tauber, C., La Joie, R., Tafani, M., Hommet, C., Chételat, G., Mondon, K., de La Sayette, V., Cottier, J.P., Beaufils, E., Ribeiro, M.J., Gissot, V., Vierron, E., Vercouillie, J., Vellas, B., Eustache, F., Guilloteau, D.: Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur. J. Nucl. Med. Mol. Imaging 39(4), 621–631 (2012)
Ashgar, M., Hinz, R., Herholz, K., Carter, S.F.: Dual-phase [18F]florbetapir in frontotemporal dementia. Eur. J. Nucl. Med. Mol. Imaging 46(2), 304–311 (2019)
Acknowledgments
This work was supported partly by an FPU Fellowship (Beca de Formación de Profesorado Universitario) from the Spanish Ministry of Education, Culture and Sport (MECD) granted to Alexander P. Seiffert (FPU16/06487).
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Ethics declarations
None.
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this paper
Cite this paper
Seiffert, A.P. et al. (2020). Quantitative Analysis of Brain 18F-fluordesoxyglucose and Early-Phase 18F-florbetapir Positron Emission Tomography. In: Henriques, J., Neves, N., de Carvalho, P. (eds) XV Mediterranean Conference on Medical and Biological Engineering and Computing – MEDICON 2019. MEDICON 2019. IFMBE Proceedings, vol 76. Springer, Cham. https://doi.org/10.1007/978-3-030-31635-8_52
Download citation
DOI: https://doi.org/10.1007/978-3-030-31635-8_52
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-31634-1
Online ISBN: 978-3-030-31635-8
eBook Packages: EngineeringEngineering (R0)